RJFSA
MIRM icon

Raymond James Financial Services Advisors’s Mirum Pharmaceuticals MIRM Stock Holding History

Raymond James Financial Services Advisors’s Portfolio MIRM Stock Details MIRM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		$4.27M Buy
109,545
+10,662
+11% +$425K 0.01% 1309
2024
Q2 		$3.38M Buy
98,883
+992
+1% +$26K ﹤0.01% 1371
2024
Q1 		$2.46M Buy
97,891
+37,844
+63% +$1.04M ﹤0.01% 1544
2023
Q4 		$1.77M Buy
60,047
+10,156
+20% +$307K ﹤0.01% 1637
2023
Q3 		$1.58M Buy
49,891
+11,862
+31% +$325K ﹤0.01% 1642
2023
Q2 		$984K Sell
38,029
-1,370
-3% -$36.4K ﹤0.01% 1935
2023
Q1 		$946K Sell
39,399
-7,853
-17% -$179K ﹤0.01% 1927
2022
Q4 		$921K Sell
47,252
-3,025
-6% -$59.8K ﹤0.01% 1887
2022
Q3 		$1.06M Sell
50,277
-15,542
-24% -$374K ﹤0.01% 1769
2022
Q2 		$1.28M Buy
65,819
+12,518
+23% +$295K ﹤0.01% 1683
2022
Q1 		$1.17M Buy
53,301
+27,979
+110% +$571K ﹤0.01% 1839
2021
Q4 		$404K Buy
25,322
+1,574
+7% +$24.5K ﹤0.01% 2516
2021
Q3 		$473K Buy
+23,748
New +$386K ﹤0.01% 2396

Other funds holding MIRM

FLSM
Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
EAM
Eventide Asset Management Boston, Massachusetts $6.05B AUM 76.64% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
RSCM
Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return
NHAS
Novo Holdings A/S Hellerup, Denmark $1.23B AUM 81.32% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Raymond James Financial Services Advisors's MIRM Position: Q3 2024 in Review

Raymond James Financial Services Advisors increased its Mirum Pharmaceuticals (MIRM) stake by 11% in Q3 2024, buying an estimated $425K and bringing the position to 109,545 shares worth $4.27M. The position accounts for 0.01% of the portfolio, ranked #1309.

Raymond James Financial Services Advisors first reported a position in MIRM in Q3 2021 and has held it in 13 quarters since. 178 funds tracked by Wall St. Rank hold MIRM as of Q3 2024.

  • Raymond James Financial Services Advisors held 109,545 shares of Mirum Pharmaceuticals worth $4.27M as of Q3 2024.
  • Raymond James Financial Services Advisors bought 10,662 Mirum Pharmaceuticals shares in Q3 2024, an estimated $425K.
  • Mirum Pharmaceuticals made up 0.01% of Raymond James Financial Services Advisors's portfolio in Q3 2024, its #1309 holding.
  • Raymond James Financial Services Advisors first reported a position in Mirum Pharmaceuticals in Q3 2021 and has held it in 13 quarters since.
  • 178 funds tracked by Wall St. Rank held Mirum Pharmaceuticals as of Q3 2024.

Based on Raymond James Financial Services Advisors's 13F filing for Q3 2024, filed 18 Oct 2024.